EP-104GI

DRUG2 trials

Sponsors

Eupraxia Pharmaceuticals Inc.

Conditions

Eosinophilic EsophagitisEosinophilic esophagitis

Phase 1

A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

RecruitingNCT05608681

Eupraxia Pharmaceuticals Inc.Eosinophilic Esophagitis

Start: 2023-03-31End: 2026-12-01Target: 117Updated: 2026-03-19

A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP 104GI in Adults with Eosinophilic Esophagitis (RESOLVE)

RecruitingCTIS2024-516689-13-00

Eupraxia Pharmaceuticals Inc.Eosinophilic esophagitis

Start: 2023-02-06Target: 5Updated: 2025-08-19

Related Papers

265. INITIAL RESULTS FROM RESOLVE, A PHASE 1B DOSE-ESCALATION STUDY OF EP-104GI (EXTENDED-RELEASE FLUTICASONE PROPIONATE INTRA-ESOPHAGEAL INJECTION) FOR EOSINOPHILIC ESOPHAGITIS

Diseases of the Esophagus2024-09-01